The FDA cleared the ROMA Algorithm, which uses the CA-125 and HE4 blood markers, to determine the likelihood that a pelvic mass is malignant. The test is a tool to help gynecologists appropriately refer women with masses that are likely to be malignant to a gynecologic oncologist for surgery. It is not a screening test.
Read more here
